Should CYP2D6 be genotyped when treating with tamoxifen?

Pharmacogenomics. 2016 Dec;17(18):1967-1969. doi: 10.2217/pgs-2016-0162. Epub 2016 Nov 24.

Authors

Marzia Del Re¹, Eleonora Rofi¹, Valentina Citi¹, Leonardo Fidilio¹, Romano Danesi¹

Affiliation

¹ Clinical Pharmacology & Pharmacogenetics Unit, Department of Clinical & Experimental Medicine, University of Pisa, 55 Via Roma, 56126 Pisa, Italy.

PMID: 27883289
DOI: 10.2217/pgs-2016-0162

No abstract available

Keywords: CYP2D6; drug–drug interaction; pharmacogenetics; tamoxifen.

MeSH terms

Antineoplastic Agents, Hormonal / therapeutic use
Breast Neoplasms / drug therapy*
Breast Neoplasms / genetics
Cytochrome P-450 CYP2D6 / genetics*
Female
Genotype
Humans
Pharmacogenetics*
Tamoxifen / therapeutic use*

Substances

Antineoplastic Agents, Hormonal
Tamoxifen
Cytochrome P-450 CYP2D6